Welcome to our dedicated page for Carl Zeiss Medit news (Ticker: CZMWY), a resource for investors and traders seeking the latest updates and insights on Carl Zeiss Medit stock.
Carl Zeiss Meditec AG (CZMWY) delivers innovative medical technologies transforming ophthalmology and microsurgery. This news hub provides authorized updates about the company’s advancements in surgical visualization, diagnostic systems, and AI-enhanced clinical workflows.
Access official press releases covering financial results, regulatory milestones, and product innovations. Stay informed about developments in refractive laser systems, 3D surgical microscopy, and integrated digital solutions improving global eye care standards.
Key updates include earnings reports, strategic partnerships, R&D breakthroughs, and clinical study outcomes. Content is curated to support informed analysis of the company’s market position and technological leadership.
Bookmark this page for verified updates about CZMWY’s contributions to precision medicine, including advancements in cataract surgery technologies and smart diagnostic platforms. Check regularly for announcements impacting the medical device sector.
ZEISS Medical Technology has achieved a significant milestone with over 2 million cataract cases planned using the ZEISS VERACITY Surgery Planner in the U.S. This digital planning solution has demonstrated up to 60% time savings per eye compared to traditional paper planning.
The company will showcase its innovations at ASCRS 2025 in Los Angeles, including the newly available ZEISS MEL 90 and VISUMAX 800 systems for refractive treatments. The VISUMAX 800 with SMILE pro software enables faster treatment, creating lenticules in under 10 seconds with a 2 MHz laser pulse rate.
For the first time, ZEISS will present cataract surgical solutions from its companies DORC and FCI, featuring the DORC EVA NEXUS surgical system and VisionBlue anterior stain, which has been used in over 10 million cataract surgeries. The showcase will also include the FDA-approved Eyejet 20C from Morcher, designed to prevent toric IOL rotation.
ZEISS Medical Technology has received FDA 510(k) clearance for its INTRABEAM 700, an advanced platform for intraoperative radiation therapy (IORT). The system features robotic-assisted precision through the INTRABEAM SMART Stand, offering enhanced maneuverability and positioning control for neurooncology and breast cancer therapy.
The platform introduces SMART workflow efficiency with digital-first architecture, including sterile SMART Spherical Applicators, digital-assisted applicator management, and the redesigned Radiance™ treatment planning simulation software. The system enables seamless integration into hospital information systems and provides integrated applicator recognition through RFID technology.
ZEISS INTRABEAM is currently involved in multiple clinical studies, including phase 2 and 3 trials for brain metastases, glioblastoma, and breast cancer, with publications expected between 2025-2027.
ZEISS Medical Technology announced that ILM-Blue® from DORC has received NMPA approval in China, expanding its global reach. The product, used for staining and distinguishing the inner limiting membrane during vitreoretinal surgery, has been utilized in over 900,000 procedures worldwide since 2010.
ILM-Blue® is the first DORC posterior dye product available in China and remains the only ILM staining solution approved by the FDA. In the U.S., where it's marketed as TissueBlue®, it's ranked as the #1 preferred ILM stain among retina surgeons. The product helps facilitate membrane removal and reduces the risk of retinal damage during surgery.
ZEISS Medical Technology has received approval from China's National Medical Products Administration (NMPA) for its VISUMAX 800 with SMILE pro software, designed for treating nearsightedness with or without astigmatism. This latest femtosecond laser system enters the Chinese market after successful treatment of over 10 million eyes worldwide.
The system offers significant improvements including:
- Faster treatment with lenticule creation in under 10 seconds using 2 MHz laser pulse rate
- Enhanced workflow features including CentraLign centration aid and OcuLign cyclotorsion adjustment
- VISULYZE user nomograms for data collection and analysis
- Smaller footprint and compatibility with various patient beds
ZEISS Medical Technology announced FDA approval for its MEL 90 excimer laser, receiving simultaneous approval for treating myopia, hyperopia, and mixed astigmatism. The technology integrates with the VISUMAX 800 with SMILE pro, enhancing ZEISS' laser vision correction market leadership.
The MEL 90 features Triple-A (Advanced Ablation Algorithm) technology, offering high accuracy and tissue-saving ablation. It can ablate 1 diopter in 1.3 seconds during LASIK procedures at 500 Hz. The system includes an active eye tracker, intuitive interface, and flexible touch screen positioning for improved workflow efficiency.
This approval completes ZEISS' Corneal Refractive Workflow, providing U.S. surgeons with an integrated system for enhanced patient outcomes and practice efficiency. The technology is immediately available in the U.S. market.
ZEISS Medical Technology is showcasing new digital enhancements and surgical solutions at the American Academy of Ophthalmology (AAO) conference from Oct. 19-21, 2024, in Chicago. Key highlights include:
- Introduction of ZEISS VisioGen, an AI-driven solution for enhancing refractive patient communication and streamlining clinic operations
- Celebration of 10 million eyes treated with ZEISS SMILE and ZEISS SMILE pro lenticule extraction solutions
- Marking 25 years of leadership in optical biometry with ZEISS IOLMaster biometers
- Demonstration of the FDA-cleared ZEISS MICOR 700, the first hand-held lens removal device with ultrasound-free operation
- Expansion of the ZEISS Retina Workflow to include advanced vitreoretinal surgical solutions from DORC
- FDA clearance for next-generation ZEISS VISULAS combi and green therapeutic lasers
These innovations aim to advance clinical workflows and support personalized care across cataract, corneal refractive, retina, and glaucoma treatments.
ZEISS Medical Technology has launched the KINEVO® 900 S, its latest Robotic Visualization System® for neurosurgery, at the Congress of Neurological Surgeons in Houston. This system, an evolution of the successful ZEISS KINEVO 900 platform, offers enhanced digital visualization, collaborative assistant functions, and connected intelligence for complex surgical procedures.
Key features include:
- 4K 3D digital image quality with a new DepthPro Mode
- Hybrid visualization concept for uninterrupted workflow
- Cobotic assistant with AI-powered functions like AutoCenter
- Connected digital solutions for data management and collaboration
- ZEISS OPTIME complete+ service plan with 98% uptime guarantee
The KINEVO 900 S will be gradually available in all existing markets following its launch.
ZEISS Medical Technology has announced the broad U.S. distribution of the MICOR® 700, the first hand-held ultrasound-free lens removal device. This revolutionary device uses the ZEISS NULEX (non-ultrasonic lens extraction) procedure to broaden surgeons' intraocular working space, minimize risk to surrounding eye structures, and increase operating room efficiency.
Key features of the ZEISS MICOR 700 include:
- Patented crystalline lens extraction technology
- Blunt and rounded tip design
- Single-use "plug & play" system with minimal O.R. footprint
- Less thermal energy delivery than phaco
- Cavitation-free lens removal
- Disposable fluidics system to mitigate cross-contamination risk
The device is FDA approved and commercially available in the U.S. It will be demonstrated at the American Academy of Ophthalmology (AAO) conference from Oct. 19 – 21, 2024, in Chicago.
ZEISS Medical Technology is showcasing innovative solutions for retinal patient care at EURETINA 2024. Key highlights include:
- The ARTEVO 850 3D digital visualization system for ophthalmic surgery, offering customizable 3D visualization and integrated intraoperative OCT
- Single-use Lenses for ZEISS RESIGHT fundus viewing system
- The EVA NEXUS surgical system from DORC for vitreoretinal and cataract procedures
- CIRRUS PathFinder, an AI-based tool for efficient OCT data review
- A new spatial computing app for Apple Vision Pro, allowing surgeons to review 2D/3D surgery videos and patient information
These innovations aim to improve diagnosis, treatment efficiency, and patient outcomes in retinal care.
ZEISS Medical Technology is showcasing its latest innovations at the ESCRS conference, highlighting advancements in cataract and corneal refractive workflows. Key developments include:
1. ZEISS SMILE pro for hyperopia treatment in CE markets, with over 10 million eyes treated using ZEISS SMILE technology.
2. Introduction of advanced optical and digital ophthalmic microscopes: ZEISS ARTEVO 750 and ZEISS ARTEVO 850.
3. New clinical results for the AT ELANA 841P trifocal IOL.
4. AI advancements: ZEISS AI IOL Calculator (CE-marked) and CIRRUS PathFinder (pending CE mark) for improved pre-operative patient care.
5. ZEISS Surgery Optimizer with AI-based video segmentation for post-surgery analysis.
These innovations aim to enhance surgical workflows, improve patient outcomes, and pave the way for more personalized care in ophthalmology.
